MILAN (EGMN) - Figitumumab was active against refractory Ewing's sarcoma in heavily pretreated adolescents who were enrolled in a phase I/II study.Treatment with Pfizer Inc.'s investigational agent was associated with an overall response rate of 14.2%, a median progression-free survival of 1.87 months, and a median overall survival 8.87 months."This is another weapon in the fight against Ewing's sarcoma," study investigator Dr. Heribert Jürgens said at the annual congress of the European Society...